Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Taylor, A. J.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Taylor, A. J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The European Society of Cardiology 2006. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Evidence to support aggressive management of HDL-cholesterol: implications of recent trials

Allen J. Taylor

Cardiology Service, Walter Reed Army Medical Center, 6900 Georgia Ave, NW, Bldg 2, Room 4A34, Washington, DC 20307-5001, USA

Corresponding author. E-mail address: allen.taylor{at}na.amedd.army.mil

Low HDL-cholesterol is an independent risk factor for coronary disease and its prevalence is high and increasing. Lifestyle interventions are recommended for all patients at risk of cardiovascular disease, but exercise has limited effects on HDL-cholesterol. Nicotinic acid is currently the most effective pharmacological agent available for increasing levels of HDL-cholesterol. The HDL Atherosclerosis Treatment study (HATS) showed that combining nicotinic acid with a statin improved HDL-cholesterol and LDL-cholesterol, inhibited the progression of atherosclerosis, and reduced cardiovascular event rates in a high-risk population with established coronary heart disease. A prolonged-release formulation of nicotinic acid (Niaspan®) has been developed that is as effective as the immediate-release version, but is better tolerated. The double-blind, randomized Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER 2) study, and its open-label follow-up study, ARBITER 3, showed that Niaspan shares the anti-atherogenic benefits of immediate-release nicotinic acid. The Atherothrombosis Intervention in Metabolic Syndrome with Low HDL-C/High Triglyceride and Impact on Global Health Outcomes (AIM-HIGH) study will define the potential of correcting low HDL-cholesterol to improve clinical outcomes in patients with well-controlled LDL-cholesterol. In summary, the current evidence base clearly shows that aggressive intervention to correct low HDL-cholesterol as well as high LDL-cholesterol is a proven strategy for preventing atherosclerotic cardiovascular disease.

Key Words: HDL-cholesterol • Lipid profile • Nicotinic acid • Niacin • HMG-CoA reductase inhibitors • Cardiovascular risk


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.